Memorandum for the Secretary of Health and Human Services the Commissioner of Food and Drugs
This presidential memorandum addresses concerns about misleading direct-to-consumer prescription drug advertisements.
The memorandum directs the Secretary of Health and Human Services and the Commissioner of Food and Drugs to enhance transparency and accuracy in such advertising by increasing the amount of risk information provided and by rigorously enforcing existing regulations.
The goal is to ensure that consumers receive fair, balanced, and complete information to make informed healthcare decisions.
Arguments For
Intended Benefit: Improved consumer understanding of prescription drug risks and benefits, leading to more informed healthcare decisions.
Evidence Cited: The memorandum cites the 1962 Congressional authority granted to the FDA to regulate prescription drug advertising and notes that current advertising practices may mislead consumers.
Implementation Methods: The memorandum directs the Secretary of Health and Human Services and the Commissioner of Food and Drugs to take appropriate action to increase information about drug risks in advertisements and to enforce existing regulations for truthful and non-misleading advertising.
Legal/Historical Basis: The action is based on the 1962 legislation granting the FDA authority to regulate prescription drug advertising, aiming to uphold and clarify its intended purpose.
Arguments Against
Potential Impacts: Increased regulatory burden on pharmaceutical companies, potentially impacting the cost and availability of medications.
Implementation Challenges: Defining "materially complete" and "fairly balanced" information can be subjective, creating enforcement challenges. There may also be challenges in balancing consumer protection with free speech concerns.
Alternative Approaches: Alternative solutions could include educational campaigns targeting consumers, or incentivizing pharmaceutical companies to provide more complete information voluntarily.
Unintended Effects: Overly strict regulations could reduce drug advertising, limiting consumer awareness of available treatments. There's a potential for less effective communication of drug usage instructions.
SUBJECT: Addressing Misleading Direct-To-Consumer
Prescription Drug Advertisements
This section states the subject of the presidential memorandum: how to address misleading advertising of prescription drugs directly to consumers.
In 1962, the Congress vested the Food and Drug Administration (FDA) with the authority to regulate prescription drug advertising. These advertisements can mislead the public about the risks and benefits, encourage medications over lifestyle changes, inappropriately intervene in the physician-patient relationship, and advantage expensive drugs over cheaper generics.
This section provides background information by citing the 1962 legislation that gave the FDA the power to oversee prescription drug advertising.
It then highlights several potential negative consequences of misleading advertising including misrepresentation of risks and benefits, promoting medication over lifestyle approaches, interfering with the doctor-patient relationship, and favoring pricier drugs over more affordable generics.
The FDA has historically stipulated that a manufacturer, packer, or distributor must provide the public with materially complete information that fairly balances both the benefits and the risks of the drug. Over time, however, the FDA’s requirements have permitted drug companies to include less information, particularly in broadcast advertising, and drug manufacturer advertising has skyrocketed in recent decades.
The section explains that the FDA originally required comprehensive information about both drug benefits and risks.
However, regulations have evolved, allowing for less information in ads, notably in broadcast media.
The result is that drug advertising has increased significantly.
My Administration will ensure that the current regulatory framework for drug advertising results in fair, balanced, and complete information for American consumers.
The President's administration intends to guarantee that drug advertising regulations produce unbiased, balanced, and thorough information for consumers.
The Secretary of Health and Human Services shall therefore take appropriate action to ensure transparency and accuracy in direct-to-consumer prescription drug advertising, including by increasing the amount of information regarding any risks associated with the use of any such prescription drug required to be provided in prescription drug advertisements, to the extent permitted by applicable law. The Commissioner of Food and Drugs shall take appropriate action to enforce the Federal Food, Drug, and Cosmetic Act’s prescription drug advertising provisions, and otherwise ensure truthful and non-misleading information in direct-to-consumer prescription drug advertisements.
The memorandum instructs the Secretary of Health and Human Services to implement measures improving the transparency and accuracy of prescription drugs' advertisements by increasing the risk information in these ads as legally permissible.
The Commissioner of Food and Drugs is instructed to enforce the relevant sections of the Federal Food, Drug, and Cosmetic Act, therefore ensuring truthful advertising.
This memorandum is not intended to, and does not, create any right or benefit, substantive or procedural, enforceable at law or in equity by any party against the United States, its departments, agencies, or entities, its officers, employees, or agents, or any other person.
This is a standard legal disclaimer indicating that the memorandum does not create any legally enforceable rights.
DONALD J. TRUMP
This is the signature of the President.
The post Memorandum for the Secretary of Health and Human Services the Commissioner of Food and Drugs appeared first on The White House.
This is a standard White House website post publishing information.
Related
Memorial Day, 2026
* The President proclaimed Memorial Day, May 25, 2026, as a day of prayer for permanent peace, requested observance of the National Moment of Remembrance, and ordered flags flown at half-staff until noon.
Read MoreNominations Sent to the Senate
* The President transmitted two nominations—Charles Baldis for Special Counsel and Jules Hurst III for Under Secretary of Defense (Comptroller)—to the Senate for their confirmation proceedings.
Read MoreTo Implement Certain Provisions in the Consolidated Appropriations Act, 2026, and for Other Purposes
Extended duty-free treatment under AGOA and CBERA through December 31, 2026, reinstated Gabon as an AGOA beneficiary effective January 1, 2026, and ordered technical corrections to the HTSUS via annexes.
Read MoreRestoring Integrity to America’s Financial System
* Directed federal regulators to issue advisories and propose amendments to the Bank Secrecy Act to strengthen customer due diligence against illicit finance and mandated consideration of immigration-related risks in consumer credit underwriting.
Read More